{
  "resourceType" : "CodeSystem",
  "id" : "ssf-2-leukemia-codesystem-cs",
  "language" : "zh-TW",
  "text" : {
    "status" : "generated",
    "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\" xml:lang=\"zh-TW\" lang=\"zh-TW\"><p class=\"res-header-id\"><b>Generated Narrative: 代码系统 ssf-2-leukemia-codesystem-cs</b></p><a name=\"ssf-2-leukemia-codesystem-cs\"> </a><a name=\"hcssf-2-leukemia-codesystem-cs\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">Language: zh-TW</p></div><p>This case-sensitive code system <code>https://www.ghd.tw/cdm-fhir/CodeSystem/ssf-2-leukemia-codesystem-cs</code> defines the following codes:</p><table class=\"codes\"><tr><td style=\"white-space:nowrap\"><b>Code</b></td><td><b>Display</b></td></tr><tr><td style=\"white-space:nowrap\">000<a name=\"ssf-2-leukemia-codesystem-cs-000\"> </a></td><td>正常</td></tr><tr><td style=\"white-space:nowrap\">001<a name=\"ssf-2-leukemia-codesystem-cs-001\"> </a></td><td>AML with RUNX1-RUNX1T1</td></tr><tr><td style=\"white-space:nowrap\">002<a name=\"ssf-2-leukemia-codesystem-cs-002\"> </a></td><td>AML with CBFB-MYH11</td></tr><tr><td style=\"white-space:nowrap\">003<a name=\"ssf-2-leukemia-codesystem-cs-003\"> </a></td><td>Acute promyelocytic leukemia with PML-RARA</td></tr><tr><td style=\"white-space:nowrap\">004<a name=\"ssf-2-leukemia-codesystem-cs-004\"> </a></td><td>AML with KMT2A-MLLT3</td></tr><tr><td style=\"white-space:nowrap\">005<a name=\"ssf-2-leukemia-codesystem-cs-005\"> </a></td><td>AML with DEK-NUP214</td></tr><tr><td style=\"white-space:nowrap\">006<a name=\"ssf-2-leukemia-codesystem-cs-006\"> </a></td><td>AML with GATA2, MECOM</td></tr><tr><td style=\"white-space:nowrap\">007<a name=\"ssf-2-leukemia-codesystem-cs-007\"> </a></td><td>AML(megakaryoblastic) with RBM15-MKL1</td></tr><tr><td style=\"white-space:nowrap\">008<a name=\"ssf-2-leukemia-codesystem-cs-008\"> </a></td><td>AML with mutated NPM1</td></tr><tr><td style=\"white-space:nowrap\">009<a name=\"ssf-2-leukemia-codesystem-cs-009\"> </a></td><td>AML with biallelic mutation of CEBPA</td></tr><tr><td style=\"white-space:nowrap\">010<a name=\"ssf-2-leukemia-codesystem-cs-010\"> </a></td><td>AML with mutated FLT3/ITD</td></tr><tr><td style=\"white-space:nowrap\">011<a name=\"ssf-2-leukemia-codesystem-cs-011\"> </a></td><td>AML with mutated FLT3/TKD</td></tr><tr><td style=\"white-space:nowrap\">012<a name=\"ssf-2-leukemia-codesystem-cs-012\"> </a></td><td>AML with MLL-PTD (partial tandem duplication)</td></tr><tr><td style=\"white-space:nowrap\">013<a name=\"ssf-2-leukemia-codesystem-cs-013\"> </a></td><td>AML with BCR-ABL1</td></tr><tr><td style=\"white-space:nowrap\">021<a name=\"ssf-2-leukemia-codesystem-cs-021\"> </a></td><td>B lymphoblastic leukemia/lymphoma with BCR-ABL1</td></tr><tr><td style=\"white-space:nowrap\">022<a name=\"ssf-2-leukemia-codesystem-cs-022\"> </a></td><td>B-lymphoblastic leukemia/lymphoma with KMT2A-rearranged</td></tr><tr><td style=\"white-space:nowrap\">023<a name=\"ssf-2-leukemia-codesystem-cs-023\"> </a></td><td>B-lymphoblastic leukemia/lymphoma with ETV6-RUNX1 (TEL-AML1)</td></tr><tr><td style=\"white-space:nowrap\">024<a name=\"ssf-2-leukemia-codesystem-cs-024\"> </a></td><td>B-lymphoblastic leukemia/lymphoma with IGH/IL3</td></tr><tr><td style=\"white-space:nowrap\">025<a name=\"ssf-2-leukemia-codesystem-cs-025\"> </a></td><td>B-lymphoblastic leukemia/lymphoma with TCF3-PBX1 (E2A-PBX1)</td></tr><tr><td style=\"white-space:nowrap\">041<a name=\"ssf-2-leukemia-codesystem-cs-041\"> </a></td><td>Mixed phenotype acute leukemia with BCR-ABL1</td></tr><tr><td style=\"white-space:nowrap\">042<a name=\"ssf-2-leukemia-codesystem-cs-042\"> </a></td><td>Mixed-phenotype acute leukemia with KMT2A-rearranged</td></tr><tr><td style=\"white-space:nowrap\">051<a name=\"ssf-2-leukemia-codesystem-cs-051\"> </a></td><td>Chronic myelogenous leukemia BCR-ABL1 positive</td></tr><tr><td style=\"white-space:nowrap\">052<a name=\"ssf-2-leukemia-codesystem-cs-052\"> </a></td><td>JAK2 V617F mutation</td></tr><tr><td style=\"white-space:nowrap\">053<a name=\"ssf-2-leukemia-codesystem-cs-053\"> </a></td><td>Myeloid and lymphoid neoplasms with PDGFRA rearrangement</td></tr><tr><td style=\"white-space:nowrap\">054<a name=\"ssf-2-leukemia-codesystem-cs-054\"> </a></td><td>Myeloid and lymphoid neoplasms with PDGFRB rearrangement</td></tr><tr><td style=\"white-space:nowrap\">055<a name=\"ssf-2-leukemia-codesystem-cs-055\"> </a></td><td>Myeloid and lymphoid neoplasms with FGFR1 rearrangement</td></tr><tr><td style=\"white-space:nowrap\">090<a name=\"ssf-2-leukemia-codesystem-cs-090\"> </a></td><td>(1) 一種異常，其他上述未列之分子檢驗異常 (2) 二種異常，其中一種非上述之分子檢驗異常 (3) 二種異常，二種皆非上述之分子檢驗異常</td></tr><tr><td style=\"white-space:nowrap\">091<a name=\"ssf-2-leukemia-codesystem-cs-091\"> </a></td><td>同時有兩種(含)以上上述之分子檢驗異常</td></tr><tr><td style=\"white-space:nowrap\">092<a name=\"ssf-2-leukemia-codesystem-cs-092\"> </a></td><td>同時有三種(含)以上分子檢驗異常 (1) 三種(含)以上異常，其中一種以上非上述之分子檢驗異常 (2)三種(含)以上異常，皆非上述之分子檢驗異常</td></tr><tr><td style=\"white-space:nowrap\">8XX<a name=\"ssf-2-leukemia-codesystem-cs-8XX\"> </a></td><td>Molecular study after chemotherapy or immunotherapy or target therapy</td></tr><tr><td style=\"white-space:nowrap\">988<a name=\"ssf-2-leukemia-codesystem-cs-988\"> </a></td><td>不適用。(1) ICD-O-3 M-9811-9837 (EXCEPT C42.0, 42.1, 42.4)</td></tr><tr><td style=\"white-space:nowrap\">998<a name=\"ssf-2-leukemia-codesystem-cs-998\"> </a></td><td>有執行分子生物學檢查，但結果無法判斷</td></tr><tr><td style=\"white-space:nowrap\">999<a name=\"ssf-2-leukemia-codesystem-cs-999\"> </a></td><td>(1) 病歷未記載或不詳 (2) 未執行分子生物學檢查</td></tr></table></div>"
  },
  "url" : "https://www.ghd.tw/cdm-fhir/CodeSystem/ssf-2-leukemia-codesystem-cs",
  "version" : "1.1.0",
  "name" : "SSF2leukemiaCS",
  "title" : "SSF2 白血病-白血病分子生物學檢查的評估代碼系統",
  "status" : "active",
  "experimental" : false,
  "date" : "2024-08-01T15:33:47+08:00",
  "publisher" : "國家衛生研究院",
  "contact" : [{
    "name" : "國家衛生研究院",
    "telecom" : [{
      "system" : "url",
      "value" : "https://ghd.tw/"
    }]
  }],
  "description" : "Assessment of molecular studies in leukemia Code System",
  "jurisdiction" : [{
    "coding" : [{
      "system" : "urn:iso:std:iso:3166",
      "code" : "TW"
    }]
  }],
  "caseSensitive" : true,
  "content" : "complete",
  "count" : 33,
  "concept" : [{
    "code" : "000",
    "display" : "正常"
  },
  {
    "code" : "001",
    "display" : "AML with RUNX1-RUNX1T1"
  },
  {
    "code" : "002",
    "display" : "AML with CBFB-MYH11"
  },
  {
    "code" : "003",
    "display" : "Acute promyelocytic leukemia with PML-RARA"
  },
  {
    "code" : "004",
    "display" : "AML with KMT2A-MLLT3"
  },
  {
    "code" : "005",
    "display" : "AML with DEK-NUP214"
  },
  {
    "code" : "006",
    "display" : "AML with GATA2, MECOM"
  },
  {
    "code" : "007",
    "display" : "AML(megakaryoblastic) with RBM15-MKL1"
  },
  {
    "code" : "008",
    "display" : "AML with mutated NPM1"
  },
  {
    "code" : "009",
    "display" : "AML with biallelic mutation of CEBPA"
  },
  {
    "code" : "010",
    "display" : "AML with mutated FLT3/ITD"
  },
  {
    "code" : "011",
    "display" : "AML with mutated FLT3/TKD"
  },
  {
    "code" : "012",
    "display" : "AML with MLL-PTD (partial tandem duplication)"
  },
  {
    "code" : "013",
    "display" : "AML with BCR-ABL1"
  },
  {
    "code" : "021",
    "display" : "B lymphoblastic leukemia/lymphoma with BCR-ABL1"
  },
  {
    "code" : "022",
    "display" : "B-lymphoblastic leukemia/lymphoma with KMT2A-rearranged"
  },
  {
    "code" : "023",
    "display" : "B-lymphoblastic leukemia/lymphoma with ETV6-RUNX1 (TEL-AML1)"
  },
  {
    "code" : "024",
    "display" : "B-lymphoblastic leukemia/lymphoma with IGH/IL3"
  },
  {
    "code" : "025",
    "display" : "B-lymphoblastic leukemia/lymphoma with TCF3-PBX1 (E2A-PBX1)"
  },
  {
    "code" : "041",
    "display" : "Mixed phenotype acute leukemia with BCR-ABL1"
  },
  {
    "code" : "042",
    "display" : "Mixed-phenotype acute leukemia with KMT2A-rearranged"
  },
  {
    "code" : "051",
    "display" : "Chronic myelogenous leukemia BCR-ABL1 positive"
  },
  {
    "code" : "052",
    "display" : "JAK2 V617F mutation"
  },
  {
    "code" : "053",
    "display" : "Myeloid and lymphoid neoplasms with PDGFRA rearrangement"
  },
  {
    "code" : "054",
    "display" : "Myeloid and lymphoid neoplasms with PDGFRB rearrangement"
  },
  {
    "code" : "055",
    "display" : "Myeloid and lymphoid neoplasms with FGFR1 rearrangement"
  },
  {
    "code" : "090",
    "display" : "(1) 一種異常，其他上述未列之分子檢驗異常 (2) 二種異常，其中一種非上述之分子檢驗異常 (3) 二種異常，二種皆非上述之分子檢驗異常"
  },
  {
    "code" : "091",
    "display" : "同時有兩種(含)以上上述之分子檢驗異常"
  },
  {
    "code" : "092",
    "display" : "同時有三種(含)以上分子檢驗異常 (1) 三種(含)以上異常，其中一種以上非上述之分子檢驗異常 (2)三種(含)以上異常，皆非上述之分子檢驗異常"
  },
  {
    "code" : "8XX",
    "display" : "Molecular study after chemotherapy or immunotherapy or target therapy"
  },
  {
    "code" : "988",
    "display" : "不適用。(1) ICD-O-3 M-9811-9837 (EXCEPT C42.0, 42.1, 42.4)"
  },
  {
    "code" : "998",
    "display" : "有執行分子生物學檢查，但結果無法判斷"
  },
  {
    "code" : "999",
    "display" : "(1) 病歷未記載或不詳 (2) 未執行分子生物學檢查"
  }]
}